Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

S100A8/A9 is a valuable biomarker and treatment target to detect and modulate neutrophil involvement in myocardial infarction

Mareş, Răzvan Gheorghiţă LU ; Sabău, Adrian Horaţiu ; Cocuz, Iuliu Gabriel ; Tomuţ, Mihaela Elena ; Szabo, Istvan Adorjan ; Szőke, Andreea Raluca ; Tinca, Andreea Cătălina ; Jakobsson, Gabriel LU ; Cotoi, Ovidiu Simion LU and Şchiopu, Alexandru LU (2023) In Romanian Journal of Morphology and Embryology 64(2). p.151-158
Abstract

Myocardial infarction (MI) leads to irreversible ischemic damage of the heart muscle and is the leading cause of heart failure. The ischemic cardiac injury triggers a potent local and systemic immune response. In the acute phase post-MI, neutrophils infiltrate the myocardium in large numbers and induce further cardiomyocyte death, expanding the infarcted area. The alarmin S100A8/A9 is a proinflammatory mediator primarily produced by myeloid cells, with an emerging role in MI. We previously demonstrated that short-term inhibition of S100A8/A9 during the inflammatory phase of the immune response to MI improves long-term cardiac function. In the present study, we investigated the effects of S100A8/A9 blockade on myocardial inflammation and... (More)

Myocardial infarction (MI) leads to irreversible ischemic damage of the heart muscle and is the leading cause of heart failure. The ischemic cardiac injury triggers a potent local and systemic immune response. In the acute phase post-MI, neutrophils infiltrate the myocardium in large numbers and induce further cardiomyocyte death, expanding the infarcted area. The alarmin S100A8/A9 is a proinflammatory mediator primarily produced by myeloid cells, with an emerging role in MI. We previously demonstrated that short-term inhibition of S100A8/A9 during the inflammatory phase of the immune response to MI improves long-term cardiac function. In the present study, we investigated the effects of S100A8/A9 blockade on myocardial inflammation and post-ischemic myocardial injury in a mouse model of coronary artery ligation. Immunohistochemical (IHC) staining revealed that the presence of S100A9 is strongly correlated with neutrophil infiltration in the myocardium on days 1 and 3 post-MI. A 3-day treatment with the S100A8/A9 blocker ABR-238901 starting immediately after MI decreased the number of neutrophils and S100A9 presence in the myocardium and had a positive impact on cardiac damage, reducing infarction size. These findings promote S100A9 as an IHC biomarker of neutrophil infiltration and a promising immunomodulatory target to regulate neutrophil recruitment, reduce ischemic injury and promote long-term beneficial cardiac recovery after MI.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
infarct size, inflammation, myocardial infarction, S100A8/A9 blockade
in
Romanian Journal of Morphology and Embryology
volume
64
issue
2
pages
8 pages
publisher
Publishing House of the Romanian Academy
external identifiers
  • pmid:37518871
  • scopus:85166748031
ISSN
1220-0522
DOI
10.47162/RJME.64.2.04
language
English
LU publication?
yes
id
6f7aed54-74fc-44bd-bbc7-d52b13b0ab3c
date added to LUP
2023-11-03 11:24:27
date last changed
2024-04-19 03:31:44
@article{6f7aed54-74fc-44bd-bbc7-d52b13b0ab3c,
  abstract     = {{<p>Myocardial infarction (MI) leads to irreversible ischemic damage of the heart muscle and is the leading cause of heart failure. The ischemic cardiac injury triggers a potent local and systemic immune response. In the acute phase post-MI, neutrophils infiltrate the myocardium in large numbers and induce further cardiomyocyte death, expanding the infarcted area. The alarmin S100A8/A9 is a proinflammatory mediator primarily produced by myeloid cells, with an emerging role in MI. We previously demonstrated that short-term inhibition of S100A8/A9 during the inflammatory phase of the immune response to MI improves long-term cardiac function. In the present study, we investigated the effects of S100A8/A9 blockade on myocardial inflammation and post-ischemic myocardial injury in a mouse model of coronary artery ligation. Immunohistochemical (IHC) staining revealed that the presence of S100A9 is strongly correlated with neutrophil infiltration in the myocardium on days 1 and 3 post-MI. A 3-day treatment with the S100A8/A9 blocker ABR-238901 starting immediately after MI decreased the number of neutrophils and S100A9 presence in the myocardium and had a positive impact on cardiac damage, reducing infarction size. These findings promote S100A9 as an IHC biomarker of neutrophil infiltration and a promising immunomodulatory target to regulate neutrophil recruitment, reduce ischemic injury and promote long-term beneficial cardiac recovery after MI.</p>}},
  author       = {{Mareş, Răzvan Gheorghiţă and Sabău, Adrian Horaţiu and Cocuz, Iuliu Gabriel and Tomuţ, Mihaela Elena and Szabo, Istvan Adorjan and Szőke, Andreea Raluca and Tinca, Andreea Cătălina and Jakobsson, Gabriel and Cotoi, Ovidiu Simion and Şchiopu, Alexandru}},
  issn         = {{1220-0522}},
  keywords     = {{infarct size; inflammation; myocardial infarction; S100A8/A9 blockade}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{151--158}},
  publisher    = {{Publishing House of the Romanian Academy}},
  series       = {{Romanian Journal of Morphology and Embryology}},
  title        = {{S100A8/A9 is a valuable biomarker and treatment target to detect and modulate neutrophil involvement in myocardial infarction}},
  url          = {{http://dx.doi.org/10.47162/RJME.64.2.04}},
  doi          = {{10.47162/RJME.64.2.04}},
  volume       = {{64}},
  year         = {{2023}},
}